Interoception in Adolescents With Restrictive Eating Disorders and Autism Spectrum Disorder (INT-REDS-ASD)

November 16, 2026 updated by: Fondazione IRCCS San Gerardo dei Tintori

"Tuning Into My Body": A Study of Interoception in Adolescents With Restrictive Eating Disorders and Comorbid Autism Spectrum Disorder

The goal of this observational study is to describe interoception (the ability to sense signals from inside the body, such as heartbeat, hunger, and fullness) in three groups of adolescents aged 13 to 18: those with restrictive eating disorders (REDs), those with autism spectrum disorder (ASD), and those with both REDs and ASD.

The main questions it aims to answer are:

  • What is the level of interoceptive accuracy (how precisely participants perceive their own heartbeat), as measured by the Heartbeat Counting Task (HCT), in each of the three groups?
  • What is the level of interoceptive sensitivity (how participants self-report their awareness of body signals), as measured by the Multidimensional Assessment of Interoceptive Awareness, Version 2 (MAIA-2), in each of the three groups?

In each group, researchers will also explore whether interoceptive accuracy and sensitivity are associated with:

  • socio-demographic and clinical characteristics (gender, age, body mass index, illness duration, and IQ)
  • psychological characteristics, including alexithymia (difficulty identifying and describing emotions), eating disorder symptoms and their severity, general psychological distress, and emotion dysregulation

Participants will:

  • Complete the Heartbeat Counting Task (HCT), in which they silently count their own heartbeats
  • Fill in the MAIA-2 questionnaire about body awareness, along with other questionnaires about eating behaviors, emotions, and general well-being

All information will be collected during the standard clinical assessment, with no extra visits or procedures.

Study Overview

Detailed Description

Restrictive eating disorders (REDs), including anorexia nervosa and avoidant/restrictive food intake disorder, and autism spectrum disorder (ASD) frequently co-occur, and their overlap is associated with more severe psychopathology. Interoception, the process by which the nervous system senses, interprets, and integrates signals from inside the body, has been found to be impaired in both conditions, but little is known about interoception in adolescents with REDs and comorbid ASD.

Following the multidimensional model proposed by Garfinkel et al. (2015), this multicenter prospective observational study will assess two dimensions of interoception: interoceptive accuracy (objective performance in detecting internal body signals) and interoceptive sensitivity (self-reported perception of body signals). Three clinical groups of adolescents will be described: REDs only, ASD only, and REDs with comorbid ASD.

No study-specific procedures are planned. During the standard psychodiagnostic assessment, participants complete a modified Heartbeat Counting Task (HCT) with a time estimation control task, the MAIA-2, and other self-report questionnaires (TAS-20, EDI-3, SCL-90-R, AQ, EQ, DERS-IT-SF), and undergo cognitive assessment (WISC-V). Socio-demographic and clinical data are also collected. Interoceptive accuracy and sensitivity will be described in each group with measures of location and variability and 95% confidence intervals, and their associations with socio-demographic, clinical, and psychological variables will be explored.

Study Type

Observational

Enrollment (Estimated)

180

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Bo
      • Bologna, Bo, Italy, 40138
        • IRCCS Istituto delle Scienze Neurologiche di Bologna
        • Contact:
    • MB
    • PD
      • Padova, PD, Italy, 35128
        • Azienda Ospedale-Università Padova
        • Contact:
    • PV
      • Pavia, PV, Italy, 27100

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

13 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adolescents aged 13 to 18 years with a confirmed DSM-5-TR diagnosis of restrictive eating disorder (anorexia nervosa or avoidant/restrictive food intake disorder), autism spectrum disorder (level 1), or restrictive eating disorder with comorbid autism spectrum disorder (level 1), recruited during their standard psychodiagnostic assessment among patients under the care of four Italian child and adolescent neuropsychiatry centers: Fondazione IRCCS San Gerardo dei Tintori (Monza, coordinating center), IRCCS Istituto delle Scienze Neurologiche di Bologna, Azienda Ospedale-Università Padova, and Fondazione IRCCS Mondino (Pavia).

Description

Inclusion Criteria:

  • Confirmed diagnosis, according to DSM-5-TR criteria, of one of the following: restrictive eating disorder (anorexia nervosa or avoidant/restrictive food intake disorder); autism spectrum disorder, level 1; or restrictive eating disorder with comorbid autism spectrum disorder, level 1
  • Age between 13 and 18 years at diagnosis
  • Written informed consent freely given and obtained before the start of the study from the participant and/or parent or legal guardian

Exclusion Criteria:

  • Intellectual disability (IQ < 70)
  • Insufficient understanding of the Italian language
  • Past or current psychotic disorders

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Restrictive Eating Disorders (REDs)

Adolescents aged 13 to 18 years at diagnosis with a confirmed diagnosis of a restrictive eating disorder (anorexia nervosa or avoidant/restrictive food intake disorder) according to DSM-5-TR criteria, without autism spectrum disorder.

Autism Spectrum Disorder (ASD)

Adolescents aged 13 to 18 years at diagnosis with a confirmed diagnosis of autism spectrum disorder, level 1, according to DSM-5-TR criteria, without a restrictive eating disorder.

REDs With Comorbid ASD

Adolescents aged 13 to 18 years at diagnosis with a confirmed diagnosis of a restrictive eating disorder (anorexia nervosa or avoidant/restrictive food intake disorder) and comorbid autism spectrum disorder, level 1, according to DSM-5-TR criteria.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Interoceptive Accuracy Measured by the Heartbeat Counting Task (HCT)
Time Frame: At enrollment, during the standard diagnostic assessment

Interoceptive accuracy assessed with a modified version of the Heartbeat Counting Task. Participants silently count their heartbeats, without taking their pulse, during four randomized time intervals while heart rate is recorded with a finger pulse oximeter. The accuracy score is calculated as the mean across intervals of [1 - |(recorded heartbeats - counted heartbeats) / recorded heartbeats|] × 100. Scores range from 0 to 100, with higher scores indicating greater interoceptive accuracy.

At enrollment, during the standard diagnostic assessment
Interoceptive Sensibility Measured by the Multidimensional Assessment of Interoceptive Awareness, Version 2 (MAIA-2)
Time Frame: At enrollment, during the standard diagnostic assessment

Self-reported interoceptive sensibility assessed with the MAIA-2, a 37-item questionnaire rated on a 6-point scale (0-5). Mean scores are calculated for each of the 8 subscales (Noticing, Not-Distracting, Not-Worrying, Attention Regulation, Emotional Awareness, Self-Regulation, Body Listening, Trusting) and range from 0 to 5. Higher scores indicate greater interoceptive sensibility.

At enrollment, during the standard diagnostic assessment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlations Between Interoceptive Measures and Sociodemographic Variables
Time Frame: At enrollment, during the standard diagnostic assessment

Correlations of HCT accuracy (score 0-100) and MAIA-2 subscale scores (0-5) with gender (number of participants per category) and age (years), collected from clinical records. Analyzed in each clinical group.

At enrollment, during the standard diagnostic assessment
Correlations Between Interoceptive Measures and Clinical Variables
Time Frame: At enrollment, during the standard diagnostic assessment

Correlations of HCT accuracy (score 0-100) and MAIA-2 subscale scores (0-5) with body mass index (BMI, kg/m²), duration of illness (months), and Full Scale IQ measured by the WISC-V (standard score, mean 100, SD 15), collected from clinical records. Analyzed in each clinical group.

At enrollment, during the standard diagnostic assessment
Alexithymia Measured by the Toronto Alexithymia Scale (TAS-20)
Time Frame: At enrollment, during the standard diagnostic assessment

Alexithymia assessed with the TAS-20, a 20-item self-report questionnaire rated on a 5-point Likert scale. Total score ranges from 20 to 100 (subscales: Difficulty Identifying Feelings, Difficulty Describing Feelings, Externally Oriented Thinking); higher scores indicate greater alexithymia. Scores will be analyzed for their correlations with HCT accuracy and MAIA-2 scores in each clinical group.

At enrollment, during the standard diagnostic assessment
Eating Disorder Symptom Severity Measured by the Eating Disorder Inventory-3 (EDI-3)
Time Frame: At enrollment, during the standard diagnostic assessment

Eating disorder symptoms assessed with the EDI-3, a 91-item self-report questionnaire comprising 12 primary scales and 6 composite scales, including the Eating Disorder Risk Composite. Raw scores are converted to T-scores; higher scores indicate greater symptom severity. Scores will be analyzed for their correlations with HCT accuracy and MAIA-2 scores in each clinical group.

At enrollment, during the standard diagnostic assessment
General Psychopathology Measured by the Symptom Checklist-90-Revised (SCL-90-R)
Time Frame: At enrollment, during the standard diagnostic assessment

General psychopathology assessed with the SCL-90-R, a 90-item self-report questionnaire rated from 0 to 4, covering 9 symptom dimensions. The Global Severity Index (GSI) ranges from 0 to 4; higher scores indicate greater psychological distress. Scores will be analyzed for their correlations with HCT accuracy and MAIA-2 scores in each clinical group.

At enrollment, during the standard diagnostic assessment
Emotion Dysregulation Measured by the Difficulties in Emotion Regulation Scale - Italian Short Form (DERS-IT-SF)
Time Frame: At enrollment, during the standard diagnostic assessment

Emotion dysregulation assessed with the DERS-IT-SF, a self-report questionnaire rated on a 5-point Likert scale. Higher total and subscale scores indicate greater difficulties in emotion regulation. Scores will be analyzed for their correlations with HCT accuracy and MAIA-2 scores in each clinical group.

At enrollment, during the standard diagnostic assessment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Renata Nacinovich, Fondazione IRCCS San Gerardo dei Tintori

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

November 6, 2026

First Submitted That Met QC Criteria

November 16, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

A decision on sharing individual participant data has not yet been made. Any future sharing of pseudonymized data would take place only in accordance with the informed consent, the EU General Data Protection Regulation (GDPR), and applicable Italian data protection law.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe